-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 4th China International Import Expo has come to a successful conclusion a few days ago, and the "four-leaf clover" agreement has attracted worldwide attention
.
During this period, the "Philippines Enjoy Time·D Makes a Legend" sponsored by Sanofi, the first anniversary of the launch of insulin glargine U300, and the iGlarLixi new drug promotion event shined into the Expo
.
The event was specially invited by Professor Guo Lixin from Beijing Hospital to lead the host, Professor Peng Yongde from the First People's Hospital Affiliated to Shanghai Jiaotong University, Professor Zou Dajin from the Tenth People's Hospital Affiliated to Tongji University, Professor Chen Lulu from Wuhan Union Hospital, Professor Xue Yaoming from Nanfang Hospital Affiliated to Southern Medical University, and Affiliated to Tongji University Professor Qu Shen from the Tenth People's Hospital shared wonderfully on topics related to diabetes diagnosis and treatment and patient management, fully demonstrating the innovation drive in the field of diabetes and new achievements in health management models.
There were witty words, bursts of applause, and a lively discussion atmosphere
.
Now extract the essence to satisfy the readers
.
Transmission D energy-basic engine accelerated upgrade: the first anniversary of the launch of insulin glargine U300 In 2020, the innovative ultra-long-acting basal insulin insulin glargine U300 (1.
5ml: 450 units) was officially launched in China for type 2 adults who need insulin therapy Diabetics
.
What kind of clinical experience has insulin glargine U300 brought to the market for one year? Professor Yongde Peng As an innovative product, the First People's Hospital Affiliated to Shanghai Jiaotong University, insulin glargine U300 greatly reduces the injection volume compared with U100, the absorption is more stable, and truly achieves 24-hour no peak
.
Compared with the same type of insulin, insulin glargine U300 has less blood glucose variability, more stable pharmacodynamics and pharmacokinetic characteristics, less risk of hypoglycemia, and can achieve a more stable and effective blood glucose compliance clinically
.
Professor Dajin Zou, the Tenth People's Hospital Affiliated to Tongji University, has a small injection volume of insulin glargine U300, and the injection site is not prominently swelled
.
The daily injection experience of patients is better .
Insulin glargine U300 provides patients with a safe injection therapy experience, which is a big improvement compared to other basal insulins
.
Chen Lulu Professor Wuhan Union Medical College Hospital The pharmacokinetics of insulin glargine U300 is more stable, the stability of blood sugar is better, and the effect lasts for a long time
.
At the same time, the capacity of the injection pen reaches 450 units, which prolongs the time for patients to use a single injection pen, reduces the frequency of replacement, and further improves the patient's treatment compliance
.
Professor Qu Shen compared the clinical data of insulin glargine U300, U100 and insulin degluargine from the Tenth People's Hospital of Tongji University.
We found that insulin glargine U300 brought less weight gain
.
For obese patients, the use of insulin glargine U300 benefits relatively more
.
Qi D dream-compound equipment wins at full speed: iGlarLixi's prospects can look forward to in September this year, the new drug listing application of iGlarLixi, a fixed ratio compound preparation of basal insulin and GLP-1 RA, has been formally accepted by the National Medical Products Administration
.
At the same time, the results of a phase III clinical study conducted in China have been officially announced recently.
The results show that at 30 weeks of treatment, compared with the basal insulin patient group, the average HbA1c of the iGlarLixi group reached 6.
7%, and the average drop was 1.
4 %, the proportion of HbA1c reaching the standard (HbA1c<7%) is 63%
.
In addition, the iGlarLixi group is better than basal insulin in postprandial blood glucose control and weight control, and the incidence of hypoglycemia is similar to that of the basal insulin group
.
The efficacy and safety of iGlarLixi have been confirmed
.
As a new generation of hypoglycemic drugs, what are the key innovations of iGlarLixi? Dajin Zou Professor The key innovation of iGlarLixi at the Tenth People's Hospital Affiliated to Tongji University is to improve the pathophysiological changes of hyperglycemia in more patients with type 2 diabetes
.
A large part of the clinical cause of type 2 diabetes patients is insufficient insulin secretion, and basal insulin supplements the insulin needed for the patients
.
Secondly, some type 2 diabetic patients have incretin deficiency, and GLP-1 RA occupies the main component of incretin.
It can be said that the supplement of GLP-1 RA helps to achieve better blood sugar control
.
Therefore, starting from the common pathogenesis, basal insulin mainly controls fasting hyperglycemia, while GLP-1 RA is more to control postprandial hyperglycemia, while inhibiting weight gain, and greatly reducing the number of injections
.
The combination of basal insulin and GLP-1 RA can coordinate with each other to achieve better blood sugar management and enhance the therapeutic value of the drug
.
At the same time, relevant clinical research evidence shows that iGlarLixi is more effective than basal insulin alone or GLP-1 RA or premixed insulin alone, and the number of injections for patients is greatly reduced
.
Therefore, this is an innovative compound preparation that meets clinical needs, and I am looking forward to the launch of iGlarLixi
.
Professor Yongde Peng The fixed ratio compound preparation of GLP-1 RA and basal insulin in the First People's Hospital of Shanghai Jiaotong University reduces the risk of hypoglycemia and can also achieve weight gains.
One injection can successfully achieve fasting and postprandial blood sugar.
Control
.
Professor Lulu Chen, Wuhan Union Medical College Hospital GLP-1 RA can reduce insulin resistance and improve insulin sensitivity, so it may reduce the actual dose of insulin required; combined with basal insulin can not only solve insulin deficiency, but also improve insulin resistance
.
The combination of two excellent hypoglycemic drugs has greatly improved the clinical efficacy, while reducing the uncertain risk of hypoglycemia
.
Therefore, with the improvement of the treatment or the improvement of the dosage form, the clinician's concern about hypoglycemia in the use of insulin will be greatly reduced
.
Professor Qu Shen Diabetic patients at the Tenth People's Hospital Affiliated to Tongji University are encouraged to self-control hypoglycemia and adjust drug dosages.
After iGlarLixi is launched in the future, it may be a very good support for patients to self-monitor and adjust blood sugar
.
D Forging ahead-working together with sugar: the new model of patient management, "Zhi Ai Three", is inseparable from the concerted efforts of doctors, patients and nurses for the comprehensive management of diabetes
.
The “Zhi Ai Three” project launched in 2014 is a typical paradigm.
The project connects doctors, nurses, and patients together to help patients reach better treatment goals
.
So, with the in-depth development of the "Zhi Ai Three People" project, what conveniences have been brought to clinical work? Prof.
Xue Yaoming The “Zhi Ai Three” project of Southern Hospital Affiliated to Southern Medical University adopts data-based artificial intelligence management methods to provide patients with personalized intervention methods in stages, groups of people, and all-weather
.
At the patient level, strengthen patient awareness and increase the enthusiasm of patients to actively participate in diabetes management; at the doctor level, specify individualized treatment plans for patients to strengthen patient management; for nurses, promote them to care more about patients and assist patients in managing blood sugar
.
Through the joint efforts of the three parties, it will bring patients better blood sugar control, lower risk of complications, and better quality of life
.
The "Zhi Ai Three" has now been further developed through the Internet, smart medical, artificial intelligence and other technical means.
Patients can more conveniently transmit blood glucose results to medical staff, so that medical staff can give better treatment according to blood sugar changes.
Guidance
.
Specifically, this innovative project introduces the insulin dosage loop, that is, after the patient injects insulin, the insulin dosage can be intelligently fed back to the doctors and nurses through AI.
This method can effectively guide the patients to take medicine and reduce the patient's missed injections or wrong injections.
There is a risk
.
Technology leads and product updates
.
In the field of blood sugar management, an innovation-driven "smart blood sugar reduction" storm is on the rise
.
More intelligent hypoglycemic drugs, more scientific and technological management techniques and more forward-looking management concepts, herald the arrival of a new era of blood glucose management
.
Innovation changes blood sugar, innovation creates a legend, and the scientific management of diabetes in the future will allow patients to have no waiting and fear of diabetes! 4M: MAT-CN-2129514 Plan approval date: November 2021
.
During this period, the "Philippines Enjoy Time·D Makes a Legend" sponsored by Sanofi, the first anniversary of the launch of insulin glargine U300, and the iGlarLixi new drug promotion event shined into the Expo
.
The event was specially invited by Professor Guo Lixin from Beijing Hospital to lead the host, Professor Peng Yongde from the First People's Hospital Affiliated to Shanghai Jiaotong University, Professor Zou Dajin from the Tenth People's Hospital Affiliated to Tongji University, Professor Chen Lulu from Wuhan Union Hospital, Professor Xue Yaoming from Nanfang Hospital Affiliated to Southern Medical University, and Affiliated to Tongji University Professor Qu Shen from the Tenth People's Hospital shared wonderfully on topics related to diabetes diagnosis and treatment and patient management, fully demonstrating the innovation drive in the field of diabetes and new achievements in health management models.
There were witty words, bursts of applause, and a lively discussion atmosphere
.
Now extract the essence to satisfy the readers
.
Transmission D energy-basic engine accelerated upgrade: the first anniversary of the launch of insulin glargine U300 In 2020, the innovative ultra-long-acting basal insulin insulin glargine U300 (1.
5ml: 450 units) was officially launched in China for type 2 adults who need insulin therapy Diabetics
.
What kind of clinical experience has insulin glargine U300 brought to the market for one year? Professor Yongde Peng As an innovative product, the First People's Hospital Affiliated to Shanghai Jiaotong University, insulin glargine U300 greatly reduces the injection volume compared with U100, the absorption is more stable, and truly achieves 24-hour no peak
.
Compared with the same type of insulin, insulin glargine U300 has less blood glucose variability, more stable pharmacodynamics and pharmacokinetic characteristics, less risk of hypoglycemia, and can achieve a more stable and effective blood glucose compliance clinically
.
Professor Dajin Zou, the Tenth People's Hospital Affiliated to Tongji University, has a small injection volume of insulin glargine U300, and the injection site is not prominently swelled
.
The daily injection experience of patients is better .
Insulin glargine U300 provides patients with a safe injection therapy experience, which is a big improvement compared to other basal insulins
.
Chen Lulu Professor Wuhan Union Medical College Hospital The pharmacokinetics of insulin glargine U300 is more stable, the stability of blood sugar is better, and the effect lasts for a long time
.
At the same time, the capacity of the injection pen reaches 450 units, which prolongs the time for patients to use a single injection pen, reduces the frequency of replacement, and further improves the patient's treatment compliance
.
Professor Qu Shen compared the clinical data of insulin glargine U300, U100 and insulin degluargine from the Tenth People's Hospital of Tongji University.
We found that insulin glargine U300 brought less weight gain
.
For obese patients, the use of insulin glargine U300 benefits relatively more
.
Qi D dream-compound equipment wins at full speed: iGlarLixi's prospects can look forward to in September this year, the new drug listing application of iGlarLixi, a fixed ratio compound preparation of basal insulin and GLP-1 RA, has been formally accepted by the National Medical Products Administration
.
At the same time, the results of a phase III clinical study conducted in China have been officially announced recently.
The results show that at 30 weeks of treatment, compared with the basal insulin patient group, the average HbA1c of the iGlarLixi group reached 6.
7%, and the average drop was 1.
4 %, the proportion of HbA1c reaching the standard (HbA1c<7%) is 63%
.
In addition, the iGlarLixi group is better than basal insulin in postprandial blood glucose control and weight control, and the incidence of hypoglycemia is similar to that of the basal insulin group
.
The efficacy and safety of iGlarLixi have been confirmed
.
As a new generation of hypoglycemic drugs, what are the key innovations of iGlarLixi? Dajin Zou Professor The key innovation of iGlarLixi at the Tenth People's Hospital Affiliated to Tongji University is to improve the pathophysiological changes of hyperglycemia in more patients with type 2 diabetes
.
A large part of the clinical cause of type 2 diabetes patients is insufficient insulin secretion, and basal insulin supplements the insulin needed for the patients
.
Secondly, some type 2 diabetic patients have incretin deficiency, and GLP-1 RA occupies the main component of incretin.
It can be said that the supplement of GLP-1 RA helps to achieve better blood sugar control
.
Therefore, starting from the common pathogenesis, basal insulin mainly controls fasting hyperglycemia, while GLP-1 RA is more to control postprandial hyperglycemia, while inhibiting weight gain, and greatly reducing the number of injections
.
The combination of basal insulin and GLP-1 RA can coordinate with each other to achieve better blood sugar management and enhance the therapeutic value of the drug
.
At the same time, relevant clinical research evidence shows that iGlarLixi is more effective than basal insulin alone or GLP-1 RA or premixed insulin alone, and the number of injections for patients is greatly reduced
.
Therefore, this is an innovative compound preparation that meets clinical needs, and I am looking forward to the launch of iGlarLixi
.
Professor Yongde Peng The fixed ratio compound preparation of GLP-1 RA and basal insulin in the First People's Hospital of Shanghai Jiaotong University reduces the risk of hypoglycemia and can also achieve weight gains.
One injection can successfully achieve fasting and postprandial blood sugar.
Control
.
Professor Lulu Chen, Wuhan Union Medical College Hospital GLP-1 RA can reduce insulin resistance and improve insulin sensitivity, so it may reduce the actual dose of insulin required; combined with basal insulin can not only solve insulin deficiency, but also improve insulin resistance
.
The combination of two excellent hypoglycemic drugs has greatly improved the clinical efficacy, while reducing the uncertain risk of hypoglycemia
.
Therefore, with the improvement of the treatment or the improvement of the dosage form, the clinician's concern about hypoglycemia in the use of insulin will be greatly reduced
.
Professor Qu Shen Diabetic patients at the Tenth People's Hospital Affiliated to Tongji University are encouraged to self-control hypoglycemia and adjust drug dosages.
After iGlarLixi is launched in the future, it may be a very good support for patients to self-monitor and adjust blood sugar
.
D Forging ahead-working together with sugar: the new model of patient management, "Zhi Ai Three", is inseparable from the concerted efforts of doctors, patients and nurses for the comprehensive management of diabetes
.
The “Zhi Ai Three” project launched in 2014 is a typical paradigm.
The project connects doctors, nurses, and patients together to help patients reach better treatment goals
.
So, with the in-depth development of the "Zhi Ai Three People" project, what conveniences have been brought to clinical work? Prof.
Xue Yaoming The “Zhi Ai Three” project of Southern Hospital Affiliated to Southern Medical University adopts data-based artificial intelligence management methods to provide patients with personalized intervention methods in stages, groups of people, and all-weather
.
At the patient level, strengthen patient awareness and increase the enthusiasm of patients to actively participate in diabetes management; at the doctor level, specify individualized treatment plans for patients to strengthen patient management; for nurses, promote them to care more about patients and assist patients in managing blood sugar
.
Through the joint efforts of the three parties, it will bring patients better blood sugar control, lower risk of complications, and better quality of life
.
The "Zhi Ai Three" has now been further developed through the Internet, smart medical, artificial intelligence and other technical means.
Patients can more conveniently transmit blood glucose results to medical staff, so that medical staff can give better treatment according to blood sugar changes.
Guidance
.
Specifically, this innovative project introduces the insulin dosage loop, that is, after the patient injects insulin, the insulin dosage can be intelligently fed back to the doctors and nurses through AI.
This method can effectively guide the patients to take medicine and reduce the patient's missed injections or wrong injections.
There is a risk
.
Technology leads and product updates
.
In the field of blood sugar management, an innovation-driven "smart blood sugar reduction" storm is on the rise
.
More intelligent hypoglycemic drugs, more scientific and technological management techniques and more forward-looking management concepts, herald the arrival of a new era of blood glucose management
.
Innovation changes blood sugar, innovation creates a legend, and the scientific management of diabetes in the future will allow patients to have no waiting and fear of diabetes! 4M: MAT-CN-2129514 Plan approval date: November 2021
